HISTOLOGICAL AND MOLECULAR PARTICULARITIES OF BREAST CANCERS IN TUNISIAN POPULATION

1A Zribi, 1M Ahmad, 5S Ben Naïr, 5S Fendi, 1N Mansouri, 2R Afaoufi, 1H Mejri, 1M Balti, 1A Hadadoua, 1Oncology, Hospital of Tunis, Oncology, Tunis, Tunisia; 2Military Hospital of Tunis, Oncology, Tunis, Tunisia

43% of all cases and in 73% of triple negative BC. SBR 2 cases were ductal, Axillary lymph nodes were involved in

Methods A retrospective study was conducted between January 2011 and December 2018 in our department. A total of 93 cases of BC, using immunohistochemistry, were classified into 4 major molecular subtypes: luminal A, luminal B, HER2-positive, and triple negative

Results Luminal A (50%) subtype was the most prevalent, followed by triple negative (20%), HER2-positive (16%), and luminal B (14%). Median age was 45 years. 90% of cases were ductal, Axillary lymph nodes were involved in 43% of all cases and in 73% of triple negative BC. SBR 2–3 was found in 64% of all cases and in 100% of luminal B BC. Ki67>20 was observed in 92%, 71%, 63% and 5% of luminal B, HER2-positive, triple negative and luminal A respectively. The DFS at 5 years was 88%. metastatic relapse was observed in 72% of all population and in 10% of triple negative subtype. Visceral metastases were observed in 100% of triple negative BC while bone metastases were diagnosed in 60% of luminal Asubtype. In LuminaA subtype, median DFS and OS were respectively 54.4 and 58.4 months, followed by triple-negative (50.9 and 56.8 months), then HER2-positive (41.7 and 47.4 months) and finally the worst survivals were attributed to luminal B subtype (31.3 and 37.3 months).

Conclusions Our study demonstrated that luminal B BC were characterized by a poor prognosis probably because of the underestimation of their aggressiveness and consequently of the less intensive therapeutic management than necessary.